Glaucoma

Increased Optic Nerve Head Capillary Blood Flow in Early Primary Open-Angle Glaucoma

Stuart K. Gardiner, Grant Cull, Brad Fortune, and Lin Wang
Devers Eye Institute, Legacy Health, Portland, Oregon, United States

Correspondence: Stuart K. Gardiner, Devers Eye Institute, Legacy Health, 1225 NE 2nd Avenue, Portland, OR 97232, USA; sgardiner@deverseye.org.
Submitted: April 23, 2019
Accepted: June 21, 2019

PURPOSE. Blood flow in the optic nerve head (ONH) is known to be reduced in eyes with advanced glaucoma. However, experimental results from non-human primates suggest an initial increase in ONH blood flow at the earliest stages of damage. This study assesses flow and pulsatile hemodynamics across a range of severities to test the hypothesis that this also occurs in human glaucoma.

METHODS. Laser speckle flowgraphy was used to measure average mean blur rate (MBRave) within ONH tissue (a correlate of capillary blood flow) and the pulsatile waveform in 93 eyes with functional loss and 74 glaucoma suspect/fellow eyes without functional loss. These were compared against results from 92 healthy control eyes. Parameters produced by the instrument’s software were age-corrected, then compared between groups using generalized estimating equation models.

RESULTS. The mean MBRave in the control eyes was 12.5 units. In glaucoma suspect/fellow eyes, the mean was 16.4 units, higher with $P < 0.0001$. In eyes with functional loss, the mean was 13.8 units, lower than eyes without functional loss with $P < 0.0001$, although still higher than control eyes with $P = 0.0096$. Analysis of the pulsatile waveform suggested that the deceleration in flow as it approaches its maximum across the cardiac cycle was delayed in glaucoma.

CONCLUSIONS. Blood flow within ONH capillaries was higher in glaucoma suspect eyes than in healthy controls. It was less elevated in eyes that had developed functional loss. The mechanisms causing these changes and their relation to concurrent changes in pulsatile hemodynamics remain under investigation.

Keywords: blood flow, optic nerve head, laser speckle flowgraphy, glaucoma, pulse cycle

It has long been known that ocular blood flow is compromised in eyes with primary open-angle glaucoma (POAG), but it remains unclear whether these changes are a primary insult, a consequence of optic neuropathy, or a combination of the two. The majority of studies have shown significantly reduced ocular blood flow in eyes with manifest glaucoma. However, there are also reports showing little or no change in blood flow. Intriguingly, while overall blood flow in the retina is lower in glaucomatous eyes than in normal eyes, during the early stage of the disease blood flow has been reported to be inversely correlated with retinal nerve fiber layer thickness (RNFLT), that is, the thinner the RNFLT, the higher the blood flow. At later stages, it was postulated that this inverse correlation eventually “burns out” with a continuing decrease in blood flow accompanying further RNFL thinning. The discrepancies among these studies might therefore be attributable to the subjects being at different stages of the disease.

Within the optic nerve head (ONH), substantial variations in the change in blood flow have been found between individuals in non-human primate models of experimental glaucoma. In a study by Quigley et al., while most eyes with chronic IOP elevation showed decreased blood flow in ONH, a third of the eyes showed a slight increase, resulting in an overall lack of correlation between blood flow and severity of damage. In that study, blood flow was measured at a late stage of the disease, up to 20 months after moderate IOP elevation.

In a recent study using a similar experimental model in our lab, ONH blood flow was measured using laser speckle flowgraphy (LSFG). Raw data from the LSFG is reported as the mean blur rate (MBR), which has been shown to be linearly correlated with capillary blood flow, allowing a more direct assessment of blood flow than is possible when relying on the density of perfused vessels measured by optical coherence tomography angiography (OCTA). Eyes were followed longitudinally, with weekly LSFG scans from baseline measurements prior to the initial IOP insult until up to 60% loss of RNFLT had occurred. Prior to approximately 10% RNFLT loss, the ONH blood flow increased by 9% (±10%) compared to baseline, causing an inverse relation with RNFLT similar to that reported for blood flow in the major retinal arteries. However, after that point, blood flow then steadily declined to 40% of its baseline level. An initial increase in ONH blood flow could occur as a consequence of autoregulation disruption. Since most clinical studies used cross-sectional designs and measured blood flow at different stages of the disease, any increase in blood flow at the earliest stage of glaucomatous pathophysiology could be obscured by a decrease in blood flow during later stages of the disease.

LSFG analyzes blood flow based on averaging a series of pulsatile blood flow waves over several cardiac cycles across a period of 4 seconds. As such, it is able to parameterize and hence quantify aspects of the pulsatile waveform, potentially...
revealing insights into pathophysiological changes in the response across the cardiac cycle. Though the physiological specifications of these parameters have not been systematically investigated, multiple studies have shown they can be used to reveal hemodynamic differences in glaucoma.\textsuperscript{10,12-15} This suggests that LSFG may provide a way to assess and quantify changes in both ONH blood flow and its pulsatile variation in vivo in human glaucoma.

In this current study, we aimed to determine whether our previous observations in an experimental model of glaucoma translated to clinical studies of human patients and to further elucidate the role that changes in ONH blood flow may have in the pathophysiology of glaucoma. We used the LSFG technique to measure ONH blood flow (using MBR) and parameters of the pulsatile waveform in cohorts comprising eyes with glaucomatous visual field loss, glaucoma suspect/fellow eyes that have not yet developed detectable visual field loss, and healthy controls. We aimed to test the hypothesis that ONH blood flow is increased at the earliest stages of pathophysiology, prior to a subsequent decrease, in human glaucoma and to test whether corresponding changes are observed in pulsatile hemodynamics.

**METHODS**

**Subjects**

Blood flow measurements were compared between a cohort with glaucoma/glaucoma suspects and those from a published normative database,\textsuperscript{16} supplemented by a smaller cohort of normal subjects tested at Devers Eye Institute (Portland, OR, USA) to detect any differences that might occur due to subtle inconsistencies between instruments or testing protocols. Thus, data were used from the following three independent cohorts.

All research adhered to the tenets of the Declaration of Helsinki.

**Portland Progression Project (P3) Cohort.** One hundred sixty-seven eyes of 88 subjects with open-angle glaucoma or suspected glaucoma, as determined by the subject’s clinician, were tested at Devers Eye Institute. These cross-sectional data were collected in subjects enrolled in the ongoing longitudinal P3 study.\textsuperscript{17-19} Subjects underwent a set of functional and structural diagnostic tests once every 6 months, including standard automated perimetry (SAP) (HFAII; Carl Zeiss Meditec Inc., Dublin, CA, USA), 24-2 test pattern, and SITA Standard test strategy; optical coherence tomography (Spectralis OCT2; Heidelberg Engineering, Heidelberg, Germany); and systemic blood pressure measurement using an arm cuff. Subjects were excluded if they had significant visual field loss due to causes other than glaucoma or if they had systemic hypertension (based on the same criteria as in the Wien controls, below). If LSFG data were available for more than one time point, the most recent test was used. Both eyes were tested, even if only one had extant glaucomatous loss, on the basis that this implies that the fellow eye could be considered as a “glaucoma suspect” that is at increased risk of developing glaucomatous loss in the future.\textsuperscript{20}

**Wien Controls.** Seventy-seven eyes of 77 healthy white subjects of European descent were tested at the Medical University of Vienna. This data set was previously published in its entirety by Luft et al.\textsuperscript{16} All subjects were free of ocular disease or abnormality (as judged by the study investigators) and systemic hypertension (systolic pressure \(\geq 160\) mm Hg and/or diastolic pressure \(\geq 100\) mm Hg). Data collected under pupil dilation were used for the current study to maximize consistency with data collection in the P3 cohort. Eyes were imaged three times under mydriasis, and the average parameter values over those three images were used for the current study.

Of the 80 eyes in the original study, there were three eyes for which only two of the three obtained images were of sufficient quality, and these three eyes were excluded from the current study.

**Portland Controls.** Fifteen eyes of 15 healthy white subjects were tested at Devers Eye Institute. Subjects were recruited from a list of 42 participants who volunteered for a previous study conducted within the Devers Eye Institute. These participants had all received a comprehensive eye examination and were regarded as having normal vision and healthy eyes. Eyes were not dilated for LSFG testing in this cohort, although it should be noted that the effect of pupil dilation in the Wien controls was minimal.\textsuperscript{16}

The P3 cohort was then subdivided into 74 eyes without functional loss, defined as a glaucoma hemifield test (GHT)\textsuperscript{21} of either within normal limits or abnormally high sensitivity on that test date and 93 eyes with existing functional loss, defined as other categories of GHT.

**Laser Speckle Flowgraphy**

Measurements were performed using an LSFG instrument (LSFG-NAV1, Softcare Co., Ltd., Fukuoka, Japan) to obtain parameters of ONH blood flow and pulsatile hemodynamics. The LSFG technique used to measure blood flow has been described in detail in previous studies.\textsuperscript{9,10} In brief, a fundus camera equipped within the LSFG device was focused on a 750 \(\times\) 360 pixel area (approximately 6 \(\times\) 3.8 mm\textsuperscript{10} centered on the ONH. An 830-nm laser generates a speckle pattern due to random interference of scattered light from the illuminated tissue area. The speckle pattern is continuously imaged by a charge-coupled device at a frequency of 30 frames per second for a period of 4 seconds. The MBR of the speckle contrast within the images is computed by the manufacturer’s analysis software (LSFG Analysis; Softcare Co., Japan). MBR at a given pixel is defined based on the intensity at that pixel in that frame, at each of the eight surrounding pixels in that frame, and at each of those same nine pixels in the preceding and following frames. Specifically, MBR = (M/D)\textsuperscript{2}, where M/26 is the mean intensity across the 26 pairs of pixels (the pixel of interest and each of those 26 other pixels in turn), and D/26 is the mean difference within these pairs of pixels.\textsuperscript{22} As a ratio, MBR is reported in arbitrary units. MBR varies temporally and spatially according to the velocity of blood cell movement and correlates well with blood flow within the ONH.\textsuperscript{10,11} From a composite map of the 4-second recording of the MBR, the area corresponding to all large blood vessels within the ONH disc is masked, such that the resulting MBR values represent the capillary blood flow within the tissue. The analysis software then generates the average pulsatile waveform of MBR for a single cardiac cycle (Fig. 1). The software proceeds to generate a number of parameters from the shape of this pulsatile waveform.\textsuperscript{16} These parameters include the following:

- Average meanblur rate (MBR\textsubscript{ave}) of the tissue, defined as the mean MBR of the waveform, representing a surrogate measure of mean capillary blood flow;
- Skew, an index of the skewness of the pulsatile waveform, such that a higher value indicates that MBR decreases more rapidly from its peak;
- Blowout score (BOS), a measure of the proportion of blood flow that is maintained in the vessel between heartbeats, calculated from the average MBR and the difference of the maximum and minimum MBR of the waveform (Fig. 1);
- Blowout time (BOT), the proportion of the pulsatile waveform in which MBR is closer to its maximum than its minimum;
Analysis

Many of the LSFG parameters change with normal aging.\textsuperscript{16} Therefore, age-corrected parameters were created, adjusting each of the listed LSFG parameters to their equivalent value for a patient of age 60 years, based on linear regression against age within the Wien control eyes, under the null hypothesis that age-corrected LSFG parameters should not differ between cohorts and hence the same age correction is appropriate for all cohorts.

For the P3 cohort, each age-corrected LSFG parameter was plotted against mean deviation (MD) from SAP and compared against normative limits based on the control eyes in the Wien and Portland control cohorts combined. The values of these age-corrected parameters were formally compared between three groups of eyes: the combined set of control eyes from both cohorts; P3 eyes without existing functional loss on SAP on the day of testing; and P3 eyes with existing functional loss. These comparisons were performed using generalized estimating equation (GEE) models\textsuperscript{23} to account for intereye correlations within the P3 cohort. A subanalysis was also performed, comparing the two eyes of subjects with unilateral functional loss, that is, one eye with functional loss using the same definition as before compared with a fellow eye without functional loss.

RESULTS

Demographic information for the P3 cohort, split into \textit{without} versus \textit{with} functional loss, is shown in Table 1. The average age in the combined control eyes was 47.7 years (standard deviation (SD) 16.6; mean 48.4 years for the Wien control eyes and 44.3 years for the Portland control eyes), which was significantly younger than the average for the P3 eyes ($P < 0.0001$), underscoring the need to age-correct all LSFG parameters prior to further analysis. The mean systemic blood pressure in the Wien control eyes was 128/81, and their mean IOP was 12.8 mm Hg.\textsuperscript{16}

Without age correction, the average value of $MBR_{ave}$ in the control eyes was 13.3 units (SD 3.0). The average value in the P3 eyes without functional loss was 15.9 units (SD 3.7), which was significantly higher than the control eyes, with $P < 0.0001$ (GEE regression). The average value among P3 eyes with functional loss was 13.1 units (SD 3.5), not significantly different from the control eyes ($P = 0.8246$).

In the Wien control eyes, $MBR_{ave}$ decreased by 0.058 units per year.\textsuperscript{16} After age-correcting the data to the equivalent value for age 60 years, the average $MBR_{ave}$ among the control eyes (the combined Wien and Portland cohorts) was 12.5 units (SD 2.8), representing mean capillary blood flow within the ONH tissue. Figure 2 shows a plot of the age-corrected $MBR_{ave}$ against MD from perimetry in the P3 cohort, together with the 5th and 95th percentiles among the control eyes. The average value of $MBR_{ave}$ among P3 eyes without functional loss was 16.4 units (SD 3.6). This was significantly higher than the control eyes, with $P < 0.0001$ (GEE regression).

Among P3 eyes with functional loss, the mean value of $MBR_{ave}$ was 13.8 units (SD 3.4), which was still significantly

### Table 1. Demographic Information for Eyes in the P3 Cohort, Split According to the Presence of Significant Functional Loss (According to the Glaucoma Hemifield Test) on the Day of Testing

<table>
<thead>
<tr>
<th>Parameter</th>
<th>P3 Eyes Without Functional Loss, $n = 74$</th>
<th>P3 Eyes With Functional Loss, $n = 93$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>69.1 (8.7)</td>
<td>72.3 (8.4)</td>
</tr>
<tr>
<td>IOP, mm Hg</td>
<td>17.6 (3.5)</td>
<td>15.3 (4.3)</td>
</tr>
<tr>
<td>Systolic blood pressure, mm Hg</td>
<td>127 (18)</td>
<td>126 (17)</td>
</tr>
<tr>
<td>Diastolic blood pressure, mm Hg</td>
<td>76 (11)</td>
<td>74 (10)</td>
</tr>
<tr>
<td>MD from automated perimeter, db</td>
<td>+0.72 (1.11)</td>
<td>−4.18 (5.00)</td>
</tr>
<tr>
<td>RNFLT, μm</td>
<td>93.6 (9.2)</td>
<td>74.5 (17.7)</td>
</tr>
</tbody>
</table>

Means and standard deviations are reported per eye, not per subject. SD, standard deviation.
TABLE 2. Comparison of LSFG Parameters Between Control Eyes (Combined Portland and Wien Cohorts) and P3 Eyes Without and With Existing Functional Loss According to the Glaucoma Hemifield Test

<table>
<thead>
<tr>
<th>Age-Corrected Parameter</th>
<th>Mean (SD) in Control Eyes</th>
<th>Mean (SD) in P3 Eyes Without Functional Loss</th>
<th>Comparison P3 Eyes Without Functional Loss vs. Control Eyes</th>
<th>Mean (SD) in P3 Eyes With Functional Loss</th>
<th>Comparison P3 Eyes With Functional Loss vs. Control Eyes</th>
</tr>
</thead>
<tbody>
<tr>
<td>MBRave</td>
<td>12.5 (2.8)</td>
<td>16.4 (3.6)</td>
<td>P &lt; 0.0001</td>
<td>13.8 (3.4)</td>
<td>P = 0.0096</td>
</tr>
<tr>
<td>Skew</td>
<td>15.7 (1.7)</td>
<td>15.9 (2.1)</td>
<td>P = 0.6393</td>
<td>12.8 (2.4)</td>
<td>P = 0.0033</td>
</tr>
<tr>
<td>BOS</td>
<td>71.9 (4.8)</td>
<td>69.6 (7.1)</td>
<td>P = 0.0385</td>
<td>72.5 (7.8)</td>
<td>P = 0.6019</td>
</tr>
<tr>
<td>BOT</td>
<td>46.6 (3.5)</td>
<td>45.6 (4.7)</td>
<td>P = 0.1911</td>
<td>47.1 (4.3)</td>
<td>P = 0.3746</td>
</tr>
<tr>
<td>RR</td>
<td>12.45 (0.75)</td>
<td>12.16 (0.74)</td>
<td>P = 0.0223</td>
<td>11.90 (1.22)</td>
<td>P = 0.0006</td>
</tr>
<tr>
<td>FR</td>
<td>13.84 (0.68)</td>
<td>13.99 (0.88)</td>
<td>P = 0.2879</td>
<td>13.65 (0.87)</td>
<td>P = 0.0940</td>
</tr>
<tr>
<td>FAI</td>
<td>1.80 (0.57)</td>
<td>2.30 (0.74)</td>
<td>P &lt; 0.0001</td>
<td>1.78 (0.73)</td>
<td>P = 0.8323</td>
</tr>
<tr>
<td>ATI</td>
<td>29.5 (2.8)</td>
<td>29.7 (2.7)</td>
<td>P = 0.5356</td>
<td>30.3 (3.8)</td>
<td>P = 0.1409</td>
</tr>
<tr>
<td>RI</td>
<td>0.415 (0.056)</td>
<td>0.438 (0.076)</td>
<td>P = 0.0580</td>
<td>0.403 (0.086)</td>
<td>P = 0.3362</td>
</tr>
</tbody>
</table>

P values are from GEE models (accounting for the presence of both eyes in the P3 cohort). Bold P values indicate statistical significance.
Parameterizations of the averaged pulsatile waveform (as defined in the Methods section) plotted against MD from SAP for eyes in the P3 cohort. All parameters are corrected to the equivalent value at age 60 years. Plotting symbols are red for eyes with existing functional loss according to the Glaucoma Hemifield Test and yellow for eyes without existing functional loss. Green horizontal lines show the mean (solid line) and 5th and 95th percentiles (dashed lines) among the control eyes.
found to be a significant predictor in any of those models. In particular, the relation between MBR\textsubscript{ave} and MD was not affected by IOP in either the P3 eyes without functional loss (\(P = 0.4750\)) nor in the P3 eyes with functional loss (\(P = 0.2458\)). It should be noted, however, that P3 eyes with elevated IOP were likely to be treated, reducing the range of values and limiting the power to detect any effects.

Figure 5 shows, on the left, example pulsatile waveforms for the different study groups. In each case, in order to provide a representative example, the eye was selected to have all of MBR\textsubscript{ave}, RR, and FAI as close as possible to (and within 1 SD of) the group mean. Age-corrected values for MBR\textsubscript{ave} were 12.4 for the control eye (green, age 62 years); 15.1 for the P3 eye without functional loss (yellow, age 65 years); and 11.8 for the P3 eye with functional loss (red, age 80 years). The values of RR for the three respective eyes were 12.38, 12.25, and 12.45, respectively, and for FAI the values were 1.89, 2.06, and 1.42, respectively. It can be seen that MBR\textsubscript{ave} is consistently higher for the P3 eye without functional loss across the waveform and also that the waveform does not decelerate as quickly as the control eye when approaching its peak, as indicated by a reduced value of RR. In this particular example, the time until the waveform reached its peak was later for the P3 eye without functional loss, giving an increased value of the parameter ATI, but this was not typical of the group. This parameter did not differ significantly between the three groups, as seen in Table 2. The plot on the right of Figure 5 shows averaged waveforms for each group, defined as the mean MBR among eyes in that group at a given percentage of the way through that eye’s pulse cycle.

**DISCUSSION**

Blood flow within the capillaries of the ONH tissue was significantly higher in glaucoma suspect/fellow eyes than in healthy control eyes. In eyes with glaucomatous functional loss, a worse MD was correlated with lower blood flow. This nonmonotonic change in capillary blood flow in cross-sectional human data is consistent with longitudinal changes observed in a non-human primate model of glaucoma, whereby ONH blood flow significantly increased in the earliest stages of damage (<10% loss of RNFL) but then decreased thereafter. The fact that blood flow decreases with damage once beyond the initial stage may explain why an initial increase has not yet become dysfunctional may be acting to increase blood flow in response to increased metabolic demand as the ONH and surrounding tissues remodel in response to elevated IOP.

From the pulsatile waveform analysis, it is seen that during the increase in MBR over the first part of the cardiac cycle, this increase slows markedly in normal eyes as the MBR gradually approaches its maximum, as exemplified by the green line in Figure 5. This is reflected in a high value of the RR, meaning that in the top panel of Figure 1, the area S\(_1\) constitutes a large proportion (average 49.8% in the control eyes) of the theoretical maximum given by S\(_1\) + S\(_2\). However, in the glaucoma suspect/fellow eyes in the P3 cohort without functional loss, the MBR continues to increase rapidly as it approaches its maximum, reflected in significantly lower values of the parameter RR. This trend continues in the eyes with functional loss, which have still lower values of RR.

It is known that autoregulation, occurring primarily at the level of the arteries, is disrupted in glaucoma. It has been suggested that this could mean that blood flow drops too low when ocular perfusion pressure is reduced by elevated IOP or decreased blood pressure, resulting in the reduced ONH blood flow that has been detected in clinical studies. However, glial cells, which are reportedly activated in glaucoma, can contribute to both constriction and dilation of blood vessels. It is possible, therefore, that dysfunctional autoregulation could cause an increase in basal ONH blood flow in the ONH in early glaucoma. Alternatively, autoregulation that has not yet become dysfunctional may be acting to increase blood flow in response to increased metabolic demand as the ONH and surrounding tissues remodel in response to elevated IOP.

Glucoacma is well known to be influenced by increased IOP, which exerts mechanical load on the ONH tissue. Intriguingly, external mechanical compression of the heart has been reported to cause an increase in expression of nitric oxide, with resultant vasodilation and hence increase in coronary blood flow. Suppression of nitric oxide synthesis prevented this vasodilatory effect. An increase in unidirectional shear stress also increased nitric oxide expression in ex vivo Schlemm’s canal endothelial cells. It is plausible that mechanical compression of the ONH at the earliest stages of glaucoma may be causing a similar increase in nitric oxide expression in activated glial cells, resulting in vasodilation in the ONH and hence causing the initial increase in basal blood flow. An elevated presence of nitric oxide has been reported in the ONH of glaucomatous eyes. Nitric oxide is being investigated for its potential ability to increase outflow through the trabecular meshwork in glaucomatous eyes and it is therefore important to learn whether this would influence blood flow in the ONH.
MBRave is related to the velocity of blood flow, not just to its volume. An explanation, therefore, for changes in the pulsatile waveform could be a reduction in the ability of vessels to expand in response to moments of high flow during the pulsatile cycle. It has been shown that coronary arterioles vasodilate with decreasing pulse pressure, suggesting that increasing pulse pressure, or on pulse pressure, would allow increased flow. It seems reasonable to assume that similar pulsatile changes in vessel diameter occur in the ONH, even if those changes are too small to be easily visible. A reduction in vessel elasticity, and hence in pulsatile accommodation, would mean that the blood would have to pass through these vessels at higher velocity. Several mechanisms for such a reduction seem plausible. There is evidence that ONH tissues stiffen with aging and in glaucoma and that retinal arteries are also stiffer in late glaucoma than in healthy eyes. This stiffening may therefore prove to be the link connecting the mechanical and vascular theories of glaucoma. Alternatively, it could be caused by inflammatory mediators associated with the structural remodeling of the lamina cribrosa and prelaminal tissues in the ONH that is known to be induced by elevated IOP. There is also evidence of regulation at the level of capillaries mediated by pericytes, contractile cells that wrap around the capillary walls, and results from animal models suggest that pericytes may be compromised and/or lost in glaucoma. Such an increase in maximal blood flow velocity would result in the changes in the pulsatile waveform observed in this study, including an increase in FAI and a decrease in RR. This study does not allow us to spatially localize the observed changes in the pulsatile waveform. They could originate in the capillary bed, but they could also result from upstream changes in the retinal arteries. It is also possible that the changes in the pulsatile waveform are systemic rather than restricted to the ONH vessels, implying that the hemodynamics of an individual would influence susceptibility to glaucoma. Further studies are needed to resolve this issue.

Intuitively, it seems reasonable to hypothesize the presence of causative links between the changes in pulsatile waveform and the changes in MBRave. However, these remain speculative. An increase in blood flow caused by autoregulation could result in the retinal arterioles approaching their maximum flow capacity, which could manifest as alterations of pulsatile flow dynamics. Conversely, an increase in the maximal velocity across the cardiac cycle would be consistent with results showing that the proportion of oxygen extracted from the blood is lower in glaucomatous eyes. It can then be hypothesized that the metabolic demand, combined with reduced oxygen supply and presumably reduced carbon dioxide extraction, would cause the autoregulatory mechanisms to increase the overall blood flow into the ONH. The changes in ONH blood flow in glaucoma could even create a vicious cycle involving a combination of both altered autoregulation and altered capillary regulation.

In 48 eyes with open-angle glaucoma, Takeshima et al. found that BOS increased and RI decreased following trabeculectomy, with no accompanying change in average MBR. Similarly, in our study, as seen in Table 2, BOS was significantly higher in normal control eyes than in the P3 eyes without functional loss, with \( P = 0.039 \), while RI was lower in the normal control eyes, although with \( P = 0.058 \). This may suggest a mechanism for the protective effect of trabeculectomy on the ONH and that the early changes in hemodynamics could be reversible. However, this could also be evidence that those parameters are influenced directly by IOP, which was higher in our P3 eyes than in the control eyes (albeit not measured at exactly the same time as imaging was conducted). This potential caveat with our results could only be resolved by performing LSFG scans at different IOPs in the same eye. It should also be noted that the higher IOP in our P3 eyes without functional loss would seem unlikely to cause the observed increase in capillary blood flow in those eyes, since a 10- to 15-mm Hg elevation in IOP has been shown to have no significant effect on blood flow in a non-human primate model of glaucoma or nor on prelaminar ONH vessel density in human subjects measured by OCTA.

In 61 eyes with normal tension glaucoma, Shiga et al. found lower skew and higher ATI compared with 21 control eyes. Similarly, we found lower skew in the eyes with functional loss than in the control eyes (\( P = 0.003 \); see Table 2). However, we found no evidence of any change in skew at the earlier stage of the disease. Notably, even the mild glaucoma eyes in their study had an average MD of 3.7 dB, making them more similar to the P3 eyes with functional loss in our study. Shiga et al. have also reported reduced MBRave in a cohort of eyes with preperimetric glaucoma compared with age-matched normal eyes, but again, that cohort had a worse average MD (4.0 dB) than the P3 eyes without functional loss in the present study (3.7 dB). They were required to have a documented significant ONFL defect, suggesting that most of the eyes with preperimetric glaucoma in the Shiga et al. study may have had a slightly more advanced stage of early glaucoma than our glaucoma suspect/fellow eye group. It is also important to note that the glaucoma eyes in those studies had normal tension glaucoma, as is more prevalent in a Japanese population; it is possible that there may be important differences in blood flow and hemodynamics between normal tension glaucoma and high tension glaucoma.

The control eyes in this study were sourced from two separate populations. The two groups had significantly different MBRave, suggesting possible subtle unwritten differences in population and/or protocol. In particular, the Wien control eyes were tested under pupil dilation, while the Portland control eyes were undilated. It should be noted, however, that there was no difference in MBRave in the control eyes between dilated versus undilated states. However, even when we used only the control eyes tested in Portland, which had higher MBRave than those tested in Vienna, the MBRave was still significantly higher in the P3 eyes without functional loss (\( P = 0.048 \)) tested using the same instrument, with the higher \( P \) value compared with the primary results likely explained by the reduced sample size. A further caveat with the control eyes is that they were significantly younger, on average, than the P3 cohort (\( P < 0.001 \)). All LSFG parameters were age-corrected, but this correction necessarily assumes that the change with age remains linear even when extrapolating beyond the oldest control eye (79 years) to the oldest eye in the P3 cohort (90 years).

No significant differences in MBRave were found between treated versus untreated eyes in this cohort. Some topical medications have been reported to affect ONH blood flow, and it may be that our study was not adequately powered to detect such effects given that both the specific antiglaucoma medication and dosage were variable. Perhaps more importantly, though, the results of this subanalysis mean that the primary finding of the study, of increased MBRave in the P3 eyes without functional loss, is not caused by topical antiglaucoma medications since the difference from normal was actually slightly greater among the untreated P3 eyes.

The main criterion for inclusion in the P3 cohort was glaucoma or suspected glaucoma in at least one eye, as determined by the subject’s clinician. It is therefore possible that a subset of the P3 eyes without functional loss will in fact never go on to develop any glaucomatous functional loss, especially if the eye is only included because it is the fellow eye of an individual with unilateral glaucoma. However, the presence of these eyes actually strengthens our conclusions;
significant differences were found between the P3 eyes without functional loss and the control eyes despite the fact that there may have been some normal eyes within the glaucoma suspect/fellow eye group.

Another possible reason for the increased ONH blood flow observed in this study could be that if there has been a loss of prelaminar tissue, then the laser beam could be penetrating deeper into the ONH tissue. However, it has been shown that deeper ONH tissues have lower blood flow than do more anterior tissues. Therefore, while we cannot discount this possibility, it seems unlikely to be driving our results. A further potential caveat is that caffeine has been shown to increase blood vessel resistance within the ONH, decreasing flow. However, the control subjects in the Wien cohort were explicitly instructed to abstain from caffeine for 12 hours prior to testing, and thus this factor is unlikely to explain the Wien cohort having lower flow than the P3 cohort.

A more major caveat with our study is its cross-sectional nature. It is therefore impossible for us to know whether the P3 eyes without functional loss had previously experienced an increase in MBPlmean, as would happen if it were part of the disease process, or if they had in fact always had high MBPlmean. Either of these possibilities would have both mechanistic and diagnostic consequences, and thus it is important to now distinguish between the two. A longitudinal study to address this issue is underway.

A consequence of the nonmonotonic relation between severity and blood flow is that the parameter MBPlmean is unlikely to be useful for the diagnostic detection of disease since a value within normal limits would reappear after considerable loss of axons. This may explain why vessel density measured using OCTA has been reported as having better discriminatory power between eyes with glaucoma versus controls than do LSF parameters. Other LSF parameters may prove more useful for discrimination than MBPlave. Changes in LSF parameters may also prove useful for monitoring disease progression, and this will also be able to be assessed using the longitudinal data currently being collected.

In conclusion, we found evidence in vivo of increased capillary blood flow in the ONH in the earliest stages of human glaucoma. The blood flow appears to subsequently decrease as damage becomes more severe. Longitudinal studies are underway to confirm these changes and to learn more about their mechanistic role in glaucomatous pathophysiology.

Acknowledgments

Supported by NIH RO1-EY020922 (SKG), NIH RO1-EY019939 (LW), and unrestricted research support from The Legacy Good Samaritan Foundation, Portland, Oregon. The sponsors/funding organizations had no role in the design or conduct of this research.

Disclosure: S.K. Gardiner, None; G. Cull, None; B. Fortune, None; L. Wang, None

References


